[1]
|
Paice JA. Navigating cancer pain management in the midst of the opioid epidemic[J]. Oncology (Williston Park), 2018, 32(8):386-390. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=79234146ac2daf37529e98c9a6463ae0
|
[2]
|
Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer[J]. J Clin Oncol, 2012, 30(16):1980-1988. http://d.old.wanfangdata.com.cn/Periodical/zhcmj201612008
|
[3]
|
Wang J, Zhao Y, Wang Q, et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment[J]. Cancer Biol Med, 2018, 15(4):443-451. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzllc-e201804010
|
[4]
|
Feller L, Khammissa RAG, Bouckaert M, et al. Pain:Persistent postsurgery and bone cancer-related pain[J]. J Int Med Res, 2019, 47(2):528-543. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0229740082/
|
[5]
|
Julius D, Basbaum AI. Molecular mechanisms of nociception[J]. Nature, 2001, 413(6852):203-210. http://d.old.wanfangdata.com.cn/Conference/8590800
|
[6]
|
Mantyh P. Bone cancer pain:causes, consequences, and therapeutic opportunities[J]. Pain, 2013, 154(Suppl 1):S54-S62. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0231934161/
|
[7]
|
Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis[J]. J Bone Miner Res, 2018, 33(12):2099-2113. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_2301b90266e9ea5a596b903ef7de97a7
|
[8]
|
Park SH, Eber MR, Widner DB, et al. Role of the bone microenvironment in the development of painful complications of skeletal metastases[J]. Cancers (Basel), 2018, 10(5):141. http://cn.bing.com/academic/profile?id=420318c85f95ca0ed82ccaeaf99ab05e&encoded=0&v=paper_preview&mkt=zh-cn
|
[9]
|
Luger NM, Mach DB, Sevcik MA, et al. Bone cancer pain:from model to mechanism to therapy[J]. J Pain Symptom Manage, 2005, 29(Suppl 5):S32-S46. doi: 10.1046-j.1526-4637.2000.00047.x/
|
[10]
|
Huh Y, Ji RR, Chen G. Neuroinflammation, bone marrow stem cells, and chronic pain[J]. Front Immunol, 2017, 8:1014. http://cn.bing.com/academic/profile?id=a3046c0e95df50ff5645ca6099722f12&encoded=0&v=paper_preview&mkt=zh-cn
|
[11]
|
Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch[J]. Nat Rev Neurosci, 2019, 20(11):667-685. http://cn.bing.com/academic/profile?id=6994e658249beef0be5567aa2fcc8ffc&encoded=0&v=paper_preview&mkt=zh-cn
|
[12]
|
Berta T, Qadri Y, Tan PH, et al. Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain[J]. Expert Opin Ther Targets, 2017, 21(7):695-703. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/14728222.2017.1328057
|
[13]
|
Urch CE, Donovan-Rodriguez T, Dickenson AH. Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain[J]. Pain, 2003, 106(3):347-356. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW2017052520071421
|
[14]
|
Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients:ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4):iv166-iv191. http://cn.bing.com/academic/profile?id=cfecfbdce24d6fe4a6c3b23856b1c832&encoded=0&v=paper_preview&mkt=zh-cn
|
[15]
|
Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era[J]. CA Cancer J Clin, 2018, 68(3):182-196. http://cn.bing.com/academic/profile?id=ff8c6bced17148c25b680911ed931063&encoded=0&v=paper_preview&mkt=zh-cn
|
[16]
|
Desai SJ, Prickril B, Rasooly A. Mechanisms of phytonutrient modulation of cyclooxygenase-2(COX-2) and inflammation related to cancer[J]. Nutr Cancer, 2018, 70(3):350-375. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/01635581.2018.1446091
|
[17]
|
Wiffen PJ, Derry S, Moore RA, et al. Oral paracetamol (acetaminophen) for cancer pain[J]. Cochrane Database Syst Rev, 2017, 7:CD012637. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1002/ejp.649
|
[18]
|
Zajaczkowska R, Kocot-Kepska M, Leppert W, et al. Bone pain in cancer patients:mechanisms and current treatment[J]. Int J Mol Sci, 2019, 20(23):6047. http://cn.bing.com/academic/profile?id=85d4152170f216d9beccb9eb7e8926fb&encoded=0&v=paper_preview&mkt=zh-cn
|
[19]
|
Carmona-Bayonas A, Jimenez-Fonseca P, Castanon E, et al. Chronic opioid therapy in long-term cancer survivors[J]. Clin Transl Oncol, 2017, 19(2):236-250. http://cn.bing.com/academic/profile?id=b5a39c5db10ef94095c85db0aba9a636&encoded=0&v=paper_preview&mkt=zh-cn
|
[20]
|
Zylla D, Kuskowski MA, Gupta K, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer[J]. Br J Anaesth, 2014, 113(Suppl 1):i109-i116. http://cn.bing.com/academic/profile?id=8c86ec5c2747ad6e0a3bad0f25b1d3dd&encoded=0&v=paper_preview&mkt=zh-cn
|
[21]
|
Wang K, Zheng Y, Yang Y, et al. Nociceptin receptor is overexpressed in non-small cell lung cancer and predicts poor prognosis[J]. Front Oncol, 2019, 9:235. http://cn.bing.com/academic/profile?id=ddbb1c8bd5f831e312e229e0a5ca4dce&encoded=0&v=paper_preview&mkt=zh-cn
|
[22]
|
Sindhi V, Erdek M. Interventional treatments for metastatic bone cancer pain[J]. Pain Manag, 2019, 9(3):307-315. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=783a10527881ad7ff9014f03ec6a528e
|
[23]
|
Scott E. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer[J]. Urol Oncol, 2017, 35(3):122-123. http://cn.bing.com/academic/profile?id=8975b6b70b9ef5d6cfbe6a5f1ef20431&encoded=0&v=paper_preview&mkt=zh-cn
|
[24]
|
Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone:the OPTIMIZE-2 randomized clinical trial[J]. JAMA Oncol, 2017, 3(7):906-912. http://cn.bing.com/academic/profile?id=5d95cb846a44a697f0cd1defb2f19ba5&encoded=0&v=paper_preview&mkt=zh-cn
|
[25]
|
Yee AJ, Raje NS. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma[J]. Future Oncol, 2018, 14(3):195-203. http://cn.bing.com/academic/profile?id=5907fd258584fe79dae45a39329c0b76&encoded=0&v=paper_preview&mkt=zh-cn
|
[26]
|
Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases:results from a randomized, double-blind study of denosumab and zoledronic acid[J]. Cancer, 2013, 119(4):832-838. http://cn.bing.com/academic/profile?id=f91e865997b4f40167c819f4875fd740&encoded=0&v=paper_preview&mkt=zh-cn
|
[27]
|
Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma:an international, double-blind, double-dummy, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2018, 19(3):370-381. http://cn.bing.com/academic/profile?id=e633f4a0f01957f14b5ca5e9f897742e&encoded=0&v=paper_preview&mkt=zh-cn
|
[28]
|
Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18):a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 386(9992):433-443. http://cn.bing.com/academic/profile?id=c802439edf425aa3ec960162eb47c169&encoded=0&v=paper_preview&mkt=zh-cn
|
[29]
|
Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients:ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(Suppl 4):iv166-iv191. http://cn.bing.com/academic/profile?id=cfecfbdce24d6fe4a6c3b23856b1c832&encoded=0&v=paper_preview&mkt=zh-cn
|
[30]
|
Mantyh WG, Jimenez-Andrade JM, Stake JI, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain[J]. Neuroscience, 2010, 171(2):588-598. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=abd5365c1cd396b7dda080873be15247
|
[31]
|
Patel MK, Kaye AD, Urman RD. Tanezumab:therapy targeting nerve growth factor in pain pathogenesis[J]. J Anaesthesiol Clin Pharmacol, 2018, 34(1):111-116. http://cn.bing.com/academic/profile?id=329a5e585bd6b749a3a320d444be530e&encoded=0&v=paper_preview&mkt=zh-cn
|
[32]
|
Sopata M, Katz N, Carey W, et al. Efficacy and safety of tanezumab in the treatment of pain from bone metastases[J]. Pain, 2015, 156(9):1703-1713. http://cn.bing.com/academic/profile?id=9864aa0608172447894b47d9ad4924e7&encoded=0&v=paper_preview&mkt=zh-cn
|
[33]
|
Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases:update of an ASTRO evidence-based guideline[J]. Pract Radiat Oncol, 2017, 7(1):4-12. http://cn.bing.com/academic/profile?id=ef141f70d02bd0bbaad52f54befaed26&encoded=0&v=paper_preview&mkt=zh-cn
|
[34]
|
Chow R, Hoskin P, Hollenberg D, et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases:a systematic review and meta-analysis[J]. Ann Palliat Med, 2017, 6(2):125-142. http://cn.bing.com/academic/profile?id=04327732835d980fa7d73de00d214e5a&encoded=0&v=paper_preview&mkt=zh-cn
|
[35]
|
Dantigny R, Tanty A, Fourneret P, et al. Prevalence of pain in radiotherapy and improvement of its management[J]. Bull Cancer, 2018, 105(12):1183-1192.
|
[36]
|
Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases:an ASTRO evidence-based guideline[J]. Int J Radiat Oncol Biol Phys, 2011, 79(4):965-976. http://cn.bing.com/academic/profile?id=99f604833f0598a795ded5527f6bce31&encoded=0&v=paper_preview&mkt=zh-cn
|
[37]
|
Roque IFM, Martinez-Zapata MJ, Scott-Brown M, et al. WITHDRAWN:radioisotopes for metastatic bone pain[J]. Cochrane Database Syst Rev, 2017, 3:CD003347.
|
[38]
|
Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases:results from a phase 3, double-blind, randomised trial[J]. Lancet Oncol, 2014, 15(7):738-746. http://cn.bing.com/academic/profile?id=6c844138bbc17703f3242ae7152cec17&encoded=0&v=paper_preview&mkt=zh-cn
|
[39]
|
Amr YM, Makharita MY. Neurolytic sympathectomy in the management of cancer pain-time effect:a prospective, randomized multicenter study[J]. J Pain Symptom Manage, 2014, 48(5):944-956. http://cn.bing.com/academic/profile?id=04ef47a270364208579f37ba7c24cdc8&encoded=0&v=paper_preview&mkt=zh-cn
|
[40]
|
Candido KD, Kusper TM, Knezevic NN. New Cancer Pain Treatment Options[J]. Curr Pain Headache Rep, 2017, 21(2):12. http://cn.bing.com/academic/profile?id=00ab5b71dae46ba8d6e0f8cf209fb87b&encoded=0&v=paper_preview&mkt=zh-cn
|